- Report
- July 2026
- 145 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- July 2026
- 110 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- July 2026
- 100 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- January 2026
- 130 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- October 2025
- 196 Pages
Global
From €4539EUR$4,995USD£3,902GBP
- Report
- January 2026
- 147 Pages
Global
From €3589EUR$3,950USD£3,085GBP
- Report
- October 2025
- 210 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- February 2026
- 178 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- January 2026
- 150 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- February 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- July 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- April 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- February 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- January 2026
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- January 2026
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- January 2026
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- October 2025
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- October 2025
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- October 2025
- 160 Pages
Global
From €2871EUR$3,160USD£2,468GBP
€3589EUR$3,950USD£3,085GBP
- Report
- January 2026
- 140 Pages
Global
From €4407EUR$4,850USD£3,788GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more